The goal of this clinical research study is find the highest tolerable dose of interleukin-2
(IL-2) that can be given as an inhaled mist to patients with lung metastases. The safety of
this drug using this administration will also be studied.
IL-2 is a protein that triggers white blood cells, called natural killer cells or T-cells,
to kill cancer cells. When given as a shot or by vein, IL-2 has been known to cause fevers
and flu-like side effects, including rashes, fatigue, and extra fluid in the skin or lungs.
These symptoms are less when IL-2 is inhaled as a mist into your body.